Interferon-alpha prevents selection of doxorubicin-resistant undifferentiated-androgen-insensitive metastatic human prostate cancer cells.
Prostate
; 49(1): 19-29, 2001 Sep 15.
Article
em En
| MEDLINE
| ID: mdl-11550207
ABSTRACT
BACKGROUND:
We determined whether treatment of metastatic prostate cancer cells with doxorubicin (DOX) and interferon-alpha (IFN-alpha) prevented the emergence of highly undifferentiated tumor cells.METHODS:
The state of cell differentiation was determined by analysis of prostate-specific antigen (PSA), E-cadherin, keratin, and vimentin.RESULTS:
Human prostate cancer LNCaP-LN3 cells growing in culture as multicell spheroids expressed higher levels of E-cadherin and E-cadherin-associated beta-catenin than LNCaP-LN3 cells growing as monolayers. Treatment of cells with DOX downregulated PSA, E-cadherin, and keratin, and upregulated expression of vimentin and vascular endothelial growth factor (VEGF) mRNA. While treatment of cells with IFN-alpha did not alter gene expression, the addition of IFN-alpha to cultures treated with DOX produced synergistic toxicity and abrogated the changes in gene expression observed in cells treated with DOX alone.CONCLUSIONS:
Treatment with IFN-alpha and DOX should be further explored as a therapeutic strategy for androgen-insensitive prostate cancer.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Doxorrubicina
/
Diferenciação Celular
/
Transformação Celular Neoplásica
/
Interferon-alfa
/
Antineoplásicos
Limite:
Humans
/
Male
Idioma:
En
Revista:
Prostate
Ano de publicação:
2001
Tipo de documento:
Article
País de afiliação:
Japão